中证智能财讯南新制药（688189）2月27日晚间披露2025年业绩快报，公司实现营业收入1.42亿元，同比下降 46.09%；归母净利润亏损1.37亿元，上年同期亏损3.57亿元；扣非净利润亏损1.39亿元，上年同期亏损3.59亿元； 基本每股收益-0.5006元，加权平均净资产收益率为-15.84%。以最新收盘价计算，市净率（LF）约2.72倍，市销率 （TTM）约24.47倍。 以本次披露业绩快报数据计算，公司近年市盈率（TTM）图如下所示： 资料显示，公司主营帕拉米韦氯化钠注射液、磷酸奥司他韦干混悬剂、辛伐他汀分散片、阿托伐他汀钙片、贝那 普利氢氯噻嗪片、头孢克洛胶囊、头孢克洛干混悬剂、头孢泊肟酯干混悬剂、复方布洛芬片、布洛芬混悬滴剂、 布洛芬混悬液、盐酸非索非那定口服混悬液等。 制图数据来自恒生聚源数据库 总营收、净利季度变动情况(亿元) 2 (亿元) 1 – - 1.58 1.364 0.79 0.3580,1220.4060,2120,2130.588, 00483 -1 -2 -3 2024Q2 | -4 2024Q3 | 2025Q7 : 2025Q2 : 2023Qq 2025Q3 ; 2 ...

Group 1 - The core announcement is that Borui Pharmaceutical's wholly-owned subsidiary, Borui Pharmaceutical (Suzhou) Co., Ltd., has its products selected for the national centralized procurement program, with a procurement period extending until December 31, 2028 [2] - The selected products include Agatroban injection, Micafungin sodium for injection, Oseltamivir phosphate dry suspension, and Oseltamivir phosphate capsules [2] - The total sales of these four products for the first three quarters of 2025 are projected to be 88.8475 million yuan, accounting for 10.16% of the company's revenue [2]

Core Viewpoint - Xinhua Pharmaceutical's oseltamivir phosphate dry suspension has been approved for market launch by the National Medical Products Administration, marking a significant milestone for the company in the oral antiviral market for influenza [1][2]. Group 1: Product Approval and Market Impact - Oseltamivir phosphate is a selective neuraminidase inhibitor effective against both influenza A and B viruses, suitable for treatment and prevention in adults and children aged 2 weeks and older [1]. - The product is recognized as the first approved oral antiviral drug for influenza in China, filling a gap in the company's product line and enhancing its strategic positioning in the antiviral treatment sector [2]. - The estimated sales revenue for oseltamivir phosphate formulations in Chinese public medical institutions is approximately RMB 5.9 billion for 2024 [1]. Group 2: Clinical Significance and Usage - The dry suspension formulation is expected to become a primary treatment option for pediatric influenza due to its lower gastrointestinal side effects and ease of administration for young children [2]. - The product's design allows for precise dosage control, making it a flexible and convenient choice for influenza prevention and treatment in children [2].

Macro Highlights - The National Development and Reform Commission, Ministry of Education, and Ministry of Finance have issued a notice to improve the cost-sharing mechanism for preschool education, emphasizing the integration of fee policies with free policies and enhancing service quality [1] - The Ministry of Finance plans to issue a 2025 book-entry discount treasury bond with a total competitive bidding amount of 60 billion yuan, set to be issued at a discount price below face value [1] Market Regulation - The State Administration for Market Regulation has introduced new regulations to enforce food safety responsibilities for food sales chain enterprises, aiming to prevent systemic and regional food safety risks [2] - The Shanghai Gold Exchange has announced measures to strengthen market risk control due to recent volatility in precious metal prices, urging members to enhance risk awareness and maintain market stability [2] Autonomous Driving - Beijing has issued the first batch of L3-level highway autonomous vehicle special license plates, marking a significant milestone in the country's transition to mass production of autonomous vehicles [2][3] - The three vehicles registered for L3-level autonomous driving can operate under specific conditions, achieving a maximum speed of 80 km/h on designated highways [3] Company News - BioShares plans to increase its stake in the company by 50 million to 100 million yuan [4] - Linghuan Pharmaceutical's raw material drug, Levonorgestrel, has passed pre-certification by the World Health Organization [4] - Ningbo Construction's wholly-owned subsidiary has signed a construction contract worth 428 million yuan [4] - Yingstone Innovation has launched its Yingling A1 panoramic drone in select regional markets [4] - Zongjie Automotive has secured a new project for electric air conditioning compressor scroll plates from an international client [4] - Haizheng Pharmaceutical's subsidiary has received approval for a veterinary drug product [4] - Xinhua Pharmaceutical has obtained a drug registration certificate for Oseltamivir phosphate dry suspension [4] - *ST Songfa's subsidiary has signed contracts for the construction of eight vessels [4] - Kuangda Technology plans to establish a subsidiary in Zhuzhou as a core business hub in Central China [4] - BOE Technology Group's subsidiary has passed the listing guidance acceptance at the Beijing Stock Exchange [4] - Xiangpiaopiao intends to set up an overseas subsidiary and build a production base in Thailand [4] - Zhengdan Co. has begun trial production of a nitrogen project utilizing exhaust gas [4] - Yuanda Pharmaceutical has introduced the world's first epinephrine nasal spray for severe allergic reactions [4] - Bertley is planning to issue H-shares and list on the Hong Kong Stock Exchange [4] - Baoshan Co. has won a contract worth approximately 1.2 billion yuan for a power cable project from the Singapore Power Authority [4]

Group 1 - The Ministry of Housing and Urban-Rural Development emphasizes stabilizing the real estate market and promoting high-quality development in the sector [2] - The overall work plan for the next year includes better coordination of investments in both material and human resources, urban renewal, and enhancing urban governance [2] - The goal is to create modern, resilient, and livable cities while contributing to a good start for the 14th Five-Year Plan [2] Group 2 - Foreign institutions are increasingly optimistic about the Chinese stock market in 2026, citing improved corporate earnings and attractive valuations as key drivers [8] - Major firms like Goldman Sachs and Morgan Stanley have released positive outlooks for Chinese assets, indicating a potential rebound [8] Group 3 - The A-share market has seen a record annual trading volume exceeding 406 trillion yuan, marking a significant milestone in its history [10] - The average daily trading volume reached 1.72 trillion yuan, with several days in August and September surpassing 3 trillion yuan [10] Group 4 - Semiconductor company SMIC has implemented a price increase of approximately 10% on certain production capacities due to rising demand from mobile applications and AI [17][18] - The increase in prices is also attributed to higher raw material costs, reflecting the overall growth in semiconductor product demand [18] Group 5 - Sunac China has completed a comprehensive restructuring of its overseas debt, relieving approximately 9.6 billion USD of existing debt and significantly reducing its repayment pressure [20] - The company has also completed a restructuring of 15.4 billion yuan of domestic bonds, indicating a strategic move to stabilize its financial position [20]

Group 1 - Ningbo Huaxiang's subsidiary signed a contract for the production of robot joints, which will enhance its competitive advantage in smart robot components [1] - The contract will not significantly impact the company's current financial performance, but will positively affect future results starting from January 2026 [1] Group 2 - Jiufeng Energy's special fuel and gas supply project for the Hainan commercial space launch site is nearing completion, with products already validated through multiple rocket launches [2] - The company is advancing its Phase II expansion plan with an estimated total investment of approximately 300 million yuan [2] Group 3 - Zhenyu Technology plans to invest at least 1 billion yuan in projects related to core components for humanoid robots and other advanced technologies [3] - The company has signed strategic cooperation agreements for these investments, indicating a strong commitment to expanding its technological capabilities [3] Group 4 - Haibo Shichuang's subsidiary plans to invest 2 billion yuan in a smart green energy storage factory project, aimed at enhancing R&D and manufacturing capabilities [2] - The project is expected to positively impact the company's financial status and long-term sustainability [2] Group 5 - Various companies are involved in significant equity transfers and acquisitions, including ST Jinglan's acquisition of a 51% stake in a South African company and Jianlong Micro-Nano's 200 million yuan acquisition of a 40% stake in Hanxing Energy [5] - Other notable transactions include China Power Construction signing a contract for a Turkish gas booster station project worth approximately 6.626 billion yuan [5]

Company News - Pacific Shipping (02343.HK) plans to acquire four newly built small handy bulk carriers for USD 119 million [2] - Xinyi Energy (03868.HK) intends to acquire 100% equity of Jinzhai Xinyi Wind Power for HKD 62 million [2] - Tianjin Port Development (03382.HK) proposes to sell 60% equity of China Railway Storage and Transportation for HKD 22.5243 million, primarily engaged in coal sales [2] - Valiant Bio-B (09887.HK) announced the successful administration of LBL-024, a PD-L1/4-1BB bispecific antibody, to the first patient in the Phase Ib/II clinical trial for platinum-resistant ovarian cancer [2] - Shandong Xinhua Pharmaceutical (00719.HK) has received a drug registration certificate for its Oseltamivir phosphate dry suspension [2] - Ziyuan Yuan (08223.HK) signed a strategic cooperation framework agreement with Pengfeng Technology to explore digital transformation and asset value enhancement in the traditional Chinese medicine industry [2] - Jiaxing Gas (09908) terminated its agreement with concerted action persons [2] Financing and Buyback Activities - Yihua Tong (02402.HK) completed a placement of 8.88 million shares, raising HKD 198 million, primarily for repaying bank loans [2] - Rungao Interactive (02422.HK) plans to place up to 160 million shares at a discount of approximately 19.44%, aiming to raise about HKD 68.6 million [2] - Tencent Holdings (00700.HK) repurchased 1.051 million shares for HKD 636 million, with prices ranging from HKD 602.5 to 613.5 [3] - Kuaishou-W (01024.HK) repurchased 2.7176 million shares for HKD 174 million, with prices between HKD 63.7 and 64.65 [3] - Xiaomi Group-W (01810.HK) repurchased 3.75 million shares for HKD 147 million, with prices from HKD 39.1 to 39.28 [4] - COSCO Shipping Holdings (01919) announced a repurchase of 4.7215 million shares for approximately HKD 65.4829 million [4] - Huaxin Cement (06655.HK) major shareholder Huaxin Group plans to increase its holdings in the company's A-shares by HKD 200 million to 400 million [4]

Core Viewpoint - Xinhua Pharmaceutical has received the drug registration certificate for Oseltamivir Phosphate Suspension from the National Medical Products Administration, indicating a significant regulatory approval for the company [1] Group 1 - The company announced the approval of Oseltamivir Phosphate Suspension, which is a key product in its portfolio [1] - The registration certificate signifies compliance with national drug regulations, enhancing the company's market position [1] - This approval may lead to increased sales and market share in the antiviral medication segment [1]

Group 1 - Shareholder of Okoyi plans to reduce holdings by up to 1.89% of the company's shares, amounting to a maximum of 3 million shares due to personal funding needs [1] - Tianchuang Fashion is planning a change in control, leading to continued suspension of its stock trading, expected to last no more than 3 trading days [2] - China Electric Power Construction Company reported a new contract amount of 10,317.55 billion yuan for the first 11 months of 2025, a year-on-year decrease of 1.65% [3] Group 2 - Pilin Bio's wholly-owned subsidiary received approval for a clinical trial of a drug, indicating progress in its product development [4] - Yihong Medical obtained two medical device registration certificates for diagnostic kits, enhancing its product portfolio [5] - Aohong Electronics plans to use up to 450 million yuan of idle fundraising for cash management, targeting safe and liquid financial products [6] Group 3 - China Electric Power Construction signed a contract worth approximately 6.626 billion yuan for a natural gas booster station project in Turkey, with a construction period of about 55 months [7] - Baosheng Co. won a bid for a power cable project in Singapore, valued at around 1.2 billion yuan, marking the largest overseas order in its history [8] - *ST Xinyan's stock will resume trading on December 24, 2025, following a capital increase plan that will raise its total share capital to 3.29 billion shares [9] Group 4 - Ningbo Construction's subsidiary signed a construction contract worth 428 million yuan for an engineering project with a duration of 990 days [11] - Lianhuan Pharmaceutical's subsidiary received approval for a drug that passed the consistency evaluation for generic drugs, enhancing its market competitiveness [12] - Zhongjie Automotive received a project designation for a new electric air conditioning compressor, with expected sales of approximately 29.86 million USD over its lifecycle [13] Group 5 - Biopharmaceuticals' major shareholder plans to increase holdings by 50 million to 100 million yuan, indicating confidence in the company's future [14] - Haizheng Pharmaceutical's subsidiary received approval for a veterinary drug product, expanding its product offerings in the animal health sector [15] - *ST Songfa's subsidiary signed contracts for the construction of 8 vessels, with a total contract value between 200 million to 400 million USD [16] Group 6 - Shandong Pharmaceutical Glass announced the resignation of its chairman due to age reasons, indicating a potential leadership transition [17] - Xinno Wei's subsidiary received approval for a clinical trial of a monoclonal antibody drug, indicating advancements in its drug development pipeline [18] - Ningbo Huaxiang's subsidiary secured an order for robot joints, expected to positively impact future business performance [19][20] Group 7 - China Resources Double Crane's subsidiary received approval for a clinical trial of a drug aimed at treating a genetic eye disease, reflecting ongoing R&D efforts [21] - Huaxin Technology's shareholders set a transfer price of 56.69 yuan per share for a block of shares, indicating active shareholder engagement [22] - Xinhua Net announced the resignation of its president due to job relocation, suggesting potential changes in management [23] Group 8 - Taiji Group plans to transfer a 40% stake in a subsidiary to focus on its core pharmaceutical business, enhancing operational efficiency [24] - Huaxin Construction's shareholder plans to increase holdings by 200 million to 400 million yuan, reflecting confidence in the company's prospects [25] - Dongjie Intelligent is planning to issue shares and cash for asset acquisition, with stock trading suspended until further notice [26] Group 9 - Wanrun New Energy was designated as a delivery warehouse for lithium carbonate futures, indicating its strategic position in the market [27] - Prolo Pharmaceutical's subsidiary received a drug registration certificate for an influenza treatment, expanding its product range [28] - Saiwu Technology invested 5 million yuan in a private equity fund focused on smart vehicles and energy innovation, indicating strategic investment in growth sectors [29] Group 10 - Bohui Innovation's subsidiary received approval for a clinical trial of an immunoglobulin drug, indicating progress in its product development [30] - Bohui Innovation's subsidiary also received a drug registration certificate for a coagulation factor product, enhancing its therapeutic offerings [31] - Hanghua Co. plans to allocate 146 million yuan of surplus fundraising for a new green printing materials project, reflecting a commitment to sustainability [32] Group 11 - Nova Star Cloud obtained a loan commitment letter from a bank for a share repurchase plan, indicating financial support for its capital management strategy [33] - Jimin Health established a joint venture for technology innovation, indicating a strategic move to enhance its technological capabilities [34] - Huili Pharmaceutical received a drug registration certificate for a medication used in treating digestive ulcers, expanding its product portfolio [35]

Core Viewpoint - Xinhua Pharmaceutical has received the drug registration certificate for Oseltamivir Phosphate Dry Suspension from the National Medical Products Administration, indicating a significant advancement in its product offerings for influenza treatment and prevention [1] Group 1: Product Approval - The drug is approved for the treatment of influenza A and B in patients aged 2 weeks and older [1] - It can also be used for the prevention of influenza A and B in individuals aged 1 year and above [1]